OM1's PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training
Article content
Article content
BOSTON — OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM ® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date.
Article content
PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations.
Article content
'Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,' said Dr. Richard Gliklich, CEO of OM1. 'PhenOM is not just a model, it's an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.'
Article content
In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives.
Article content
OM1's innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1's technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company's position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development.
Article content
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
34 minutes ago
- Globe and Mail
Prediction: 3 Stocks Berkshire Hathaway Will Add to Its Portfolio After Warren Buffett Steps Down as CEO
Next year, Berkshire Hathaway will have a new CEO. Warren Buffett, who has been in charge for decades, is stepping down and Greg Abel will be taking over. It's a monumental shift for the business, and while there may not necessarily be drastic changes in the day-to-day operations, there could be some adjustments to Berkshire's holdings. There are three stocks that I think Abel should consider adding to Berkshire's portfolio once he takes over: Microsoft (NASDAQ: MSFT), Enbridge (NYSE: ENB), and Nvidia (NASDAQ: NVDA). Here's why these stocks are great long-term investments and why they fit the Berkshire mold. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Microsoft Buffett distanced himself from Microsoft because of his close association with co-founder Bill Gates. But with Buffett no longer at the helm, it opens the path for Berkshire to create a position in Microsoft under Abel. Microsoft is the type of business that checks all the boxes for Berkshire. It has solid fundamentals, many growth opportunities, and a strong brand that is known all over the world, giving it a fantastic competitive moat. In the trailing 12 months, the software company generated more than $270 billion in revenue, amassing nearly $97 billion in profit along the way. Microsoft is a leading company in artificial intelligence (AI) and cloud computing, and its office software is a staple in many businesses around the world. This is an excellent stock for investors to own for the long haul, and I think it may just be a matter of time before it finds its way into Berkshire's holdings. Enbridge With Abel being from Canada and having strong roots in Alberta, I think he'll be inclined to put his stamp on Berkshire. And what better way to do so than by opening up a position in a top oil and gas company from Canada -- Enbridge. Berkshire is no stranger to the sector and holds multiple stocks from there. Enbridge is known for its consistency and long-term dependability, which is why it also looks like a model Berkshire-type investment. This year, the company expects to meet or exceed its financial guidance, and if it does, it'll be the 20th consecutive year that Enbridge has done so. Few companies can generate that kind of consistency. And Buffett has always valued predictability and stability in businesses. The pipeline company generated revenue totaling just under 61 billion Canadian dollars over the trailing 12 months. And with Enbridge closing on multiple acquisitions in the U.S. within the past year few years, its financials could look even better in the future. Along with an attractive dividend that yields nearly 6%, this is a stock that can be ideal for any type of long-term investor. Enbridge is another stock I expect may be a staple in Berkshire's portfolio once Abel is at the helm. Nvidia For years, iPhone maker Apple has been the top holding in Berkshire's portfolio. But the company has arguably been losing its luster due to a fumbled AI rollout and delaying key features on its latest phones. And it highlights much more than that: a lack of innovation. At the very least, it's lagging behind its key rivals. A changing of the guard may be overdue at Berkshire. While Buffett has long been a fan of Apple's business, Abel may see an opportunity to change that up. Investing in Nvidia is a move that could make much more sense. Even for people who are unfamiliar with AI, investors have come to know about Nvidia's dominance in the chip world, and I believe it now has the strong brand that Apple once did, which is synonymous with innovation. Nvidia has dominant market share in the AI chip market, and its fundamentals are incredible. Over the past four quarters, it has net a profit of $77 billion on revenue of nearly $149 billion. Given its impressive market position and huge profit margins, it seems unfathomable that the stock isn't in Berkshire's portfolio already. I can only assume that it's because Buffett may not want too much exposure to tech or that he's simply too unfamiliar with it. For Abel, however, this can be yet another opportunity for him to change up Berkshire's holdings with more growth-oriented businesses. While Apple may have performed well over the past decade, it may no longer make sense for it to be Berkshire's top holding. Nvidia could be a much better fit. Should you invest $1,000 in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Enbridge, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Canadian researchers await potential update to breastfeeding guidelines for women with HIV
Researchers are waiting to see if a review by Health Canada will update guidance for mothers living with HIV who wish to breastfeed, noting the department's policy is more restrictive than those of countries such as the United States and Switzerland and runs contrary to a growing body of scientific evidence. Health Canada currently advises against breastfeeding for women living with HIV because of the risk of transmitting the virus. Women and parents living with HIV have expressed concerns about the guidance because they say breast milk strengthens a baby's immune system and helps reinforce an emotional connection between mother and child. They point to research showing that antiretroviral therapy (ART) – a combination of medications to treat HIV – can significantly reduce viral load and lower the risk of HIV transmission, even in cases of individuals living with HIV who choose to breastfeed, though it does not entirely eliminate the risk. This year, Health Canada expects to complete the initial stage of a broad review of its Nutrition for Healthy Term Infants policy. It is first looking at nutritional policy for infants from birth to six months of age. A second stage will consider nutrition for children six months to 24 months old. The department says a joint working group is leading the process and it plans to post draft guidelines online for consultation. Saskatchewan struggles to stem highest HIV rate in Canada as cases rise across the country Provinces should cover weight-loss drugs for people with pre-existing cardiovascular disease, says drug agency Jason Brophy, who chairs the Canadian Pediatric and Perinatal HIV/AIDS Research Group, said that if Health Canada's guidance is revised, breastfeeding should be recommended only for mothers with long-term viral suppression. He cautioned, though, that mothers should adhere to treatment and remain in care. 'The baby must be closely monitored by trained health care professionals,' said Dr. Brophy, a pediatric infectious disease specialist at the Children's Hospital of Eastern Ontario. His research group currently recommends formula feeding exclusively but argues that women with consistently undetectable viral loads who wish to breastfeed should receive appropriate counselling and support. Still, there are calls from within the group to go further. Mothers or parents with undetectable HIV should have equal access to both breast/chest feeding and formula feeding options, said Logan Kennedy, the research lead at Women's College Hospital in Toronto and a member of the research group. A 2019 Canadian study published in the Journal of the Pediatric Infectious Disease Society examined the use of combination antiretroviral therapy prophylaxis, a treatment that prevents the virus from replicating. It followed three breastfed infants whose mothers had sustained virologic suppression and received the therapy. All three babies remained HIV-negative. Sarah Khan, a pediatric infectious disease specialist at McMaster Children's Hospital in Hamilton, said not every baby who breastfeeds from a mother living with HIV will become infected. 'In many low-resource countries, the benefits of breastfeeding outweigh the risks, and several measures can help keep babies safe,' Dr. Khan said. In the Canadian study, she said, mothers took strict precautions to prevent breast inflammation, a known risk factor for transmission, and their newborns were given HIV medications as an additional layer of protection. In 2016, the World Health Organization recommended breastfeeding for women living with HIV on ART in low- and middle-income countries where formula may not be affordable or culturally accepted, difficult to use or continue over time or unsafe owing to unclean water. It also said countries that do not promote breastfeeding among mothers living with HIV must ensure access to lifelong ART and consistent adherence counselling. Three years later, Switzerland advised women on ART to choose either breastfeeding or formula use. In 2023, the U.S. also said mothers living with HIV who are virally suppressed should breastfeed or use formula or donor breast milk. Dr. Khan said safe breastfeeding is possible when HIV is controlled, breasts are properly cared for and preventative infant prophylaxis treatment is in place. She hopes health providers will be able to utilize new guidelines and evidence so they can have informed discussions with families affected by HIV to decide on the best approach for a mother and baby. Dr. Khan is also leading new research called the MILK Study, tracking mothers living with HIV who choose to breastfeed. There are plans to analyze breast milk during high-risk periods, such as when an infant is ill or a mother has inflammation of the breast tissue.
Globe and Mail
an hour ago
- Globe and Mail
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
Healthcare stocks are less strongly correlated with the macroeconomy, which reduces risk for investors in the stock market. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » *Stock prices used were the afternoon prices of June 9, 2025. The video was published on June 11, 2025. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
